These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 39310)

  • 1. Differential enhancement of locomotor activity by dopamine agonists following chronic morphine treatment.
    Tye NC; Horsman L; Wright FC; Pullar IA
    Psychopharmacology (Berl); 1979 May; 63(3):313-5. PubMed ID: 39310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential enhancement of locomotor activity by dopamine agonists following chronic neuroleptic treatment: an animal model of tardive dyskinesia.
    Tye NC; Horsman L; Wright FC; Pullar IA
    Eur J Pharmacol; 1979 Apr; 55(1):103-7. PubMed ID: 35357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in the effects of dopamine agonists and antagonists on general activity in rats following chronic morphine treatment.
    Smee ML; Overstreet DH
    Psychopharmacology (Berl); 1976 Sep; 49(2):125-30. PubMed ID: 825898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for increased apomorphine-sensitive dopaminergic effects after acute treatment with morphine.
    Scheel-Krüger J; Golembiowska K; Mogilnicka E
    Psychopharmacology (Berl); 1977 Jun; 53(1):55-63. PubMed ID: 407614
    [No Abstract]   [Full Text] [Related]  

  • 5. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats.
    Breese GR; Napier TC; Mueller RA
    J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine.
    Mattingly BA; Rowlett JK; Lovell G
    Psychopharmacology (Berl); 1993; 110(3):320-6. PubMed ID: 7831425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of baclofen on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity.
    Woo SH; Kim HS; Yun JS; Lee MK; Oh KW; Seong YH; Oh SK; Jang CG
    Pharmacol Res; 2001 Apr; 43(4):335-40. PubMed ID: 11352538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential behavioral and biochemical effects of four dopaminergic agonists.
    Gianutsos G; Moore KE
    Psychopharmacology (Berl); 1980; 68(2):139-46. PubMed ID: 6107946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic involvement in the mediation of morphine effects on vocalization and movement reactivity in the rat.
    Kiyatkin EA; Zhukov VN
    Int J Neurosci; 1991 May; 58(1-2):1-5. PubMed ID: 1938171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic mechanisms mediating the long-term expression of locomotor sensitization following pre-exposure to morphine or amphetamine.
    Vanderschuren LJ; Schoffelmeer AN; Mulder AH; De Vries TJ
    Psychopharmacology (Berl); 1999 Apr; 143(3):244-53. PubMed ID: 10353426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lergotrile mesylate and methysergide on morphine induced increase in prolactin release.
    Ratner A; Woo W; Yelvington D; Torres K
    Proc West Pharmacol Soc; 1981; 24():335-9. PubMed ID: 6114495
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in sensitivity to operant effects of dopaminergic and cholinergic agents following morphine withdrawal in rats.
    Glick SD; Cox RD
    Eur J Pharmacol; 1977 Apr; 42(3):303-6. PubMed ID: 558097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response shifts in the behavioural effects of dopamine agonists and antagonists following chronic morphine treatment.
    Overstreet DH; Smee ML; Woolston ME
    Proc West Pharmacol Soc; 1976; 19():248-53. PubMed ID: 1033554
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of diazepam on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity.
    Woo SH; Kim HS
    Pharmacol Res; 2001 Dec; 44(6):467-72. PubMed ID: 11735352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of selected dopaminergic agents on locomotor activity in normotensive and spontaneously hypertensive rats.
    Hynes MD; Langer DH; Hymson DL; Pearson DV; Fuller RW
    Pharmacol Biochem Behav; 1985 Sep; 23(3):445-8. PubMed ID: 4048240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine-mediated behaviour following chronic treatment with B-HT 920.
    Darmani NA; Sewell RD; Nicholls PJ
    J Pharm Pharmacol; 1988 Jul; 40(7):523-4. PubMed ID: 2905000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphine and dopamine: Low dose apomorphine can prevent both the induction and expression of morphine locomotor sensitization and conditioning.
    Leite Júnior JB; Carvalho Crespo LGS; Samuels RI; Coimbra NC; Carey RJ; Carrera MP
    Behav Brain Res; 2023 Jun; 448():114434. PubMed ID: 37100351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Ca2+ channel blockers on apomorphine, bromocriptine and morphine-induced locomotor activity in mice.
    Doğrul A; Yeşilyurt O
    Eur J Pharmacol; 1999 Jan; 364(2-3):175-82. PubMed ID: 9932721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition by ginseng total saponin of the development of morphine reverse tolerance and dopamine receptor supersensitivity in mice.
    Kin HS; Kang JG; Oh KW
    Gen Pharmacol; 1995 Sep; 26(5):1071-6. PubMed ID: 7557253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.